Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

101. Liquorice consumption and salivary testosterone concentrations. (PubMed)

Liquorice consumption and salivary testosterone concentrations. Liquorice consumption has been shown to substantially reduce serum testosterone concentration. An explanation for this result was that the active component in liquorice (glycyrrhizic acid) interfered with 17 beta-hydroxysteroid deyhydrogenase, which has been shown in vitro to catalyse the conversion of androstenedione to testosterone. We twice attempted to replicate this effect of liquorice but could not. We identified differences

2001 Lancet

102. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis

Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis Whitsel E A, Boyko E J, Matsumoto A M, Anawalt B D, Siscovick D S Authors' objectives To determine whether intramuscular administration of testosterone esters to hypogonadal men is associated with changes in plasma lipids. Searching (...) in which pre-treatment measures were recorded on a single group of patients who later received a treatment, after which post-treatment measurements were recorded. Specific interventions included in the review Intramuscular testosterone ester. The dosage of testosterone ester ranged from 50 to 250 mg every 7 to 30 days, for a duration of 1 to 24 months. Participants included in the review Male patients with non-experimental hypogonadism. Outcomes assessed in the review Studies which reported pre

2001 DARE.

103. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. (Full text)

Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. Previous studies of testosterone supplementation in HIV-infected men failed to demonstrate improvement in muscle strength. The effects of resistance exercise combined with testosterone supplementation in HIV-infected men are unknown.To determine the effects of testosterone replacement with and without resistance exercise on muscle strength and body composition in HIV-infected men (...) with low testosterone levels and weight loss.Placebo-controlled, double-blind, randomized clinical trial conducted from September 1995 to July 1998 at a general clinical research center.Sixty-one HIV-infected men aged 18 to 50 years with serum testosterone levels of less than 12.1 nmol/L (349 ng/dL) and weight loss of 5% or more in the previous 6 months, 49 of whom completed the study.Participants were randomly assigned to 1 of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk

2000 JAMA PubMed

104. Oral androstenedione administration and serum testosterone concentrations in young men. (PubMed)

Oral androstenedione administration and serum testosterone concentrations in young men. Androstenedione, a steroid hormone and the major precursor to testosterone, is available without prescription and is purported to increase strength and athletic performance. The hormonal effects of androstenedione, however, are unknown.To determine if oral administration of androstenedione increases serum testosterone levels in healthy men.Open-label randomized controlled trial conducted between October 1998 (...) and April 1999.General clinical research center of a tertiary-care, university-affiliated hospital.Forty-two healthy men aged 20 to 40 years.Subjects were randomized to receive oral androstenedione (either 100 mg/d [n = 15] or 300 mg/d [n = 14]) or no androstenedione (n = 13) for 7 days.Changes in serum testosterone, androstenedione, estrone, and estradiol levels, measured by frequent blood sampling, compared among the 3 treatment groups.Mean (SE) changes in the area under the curve (AUC) for serum

2000 JAMA

105. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. (PubMed)

Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. The ovaries provide approximately half the circulating testosterone in premenopausal women. After bilateral oophorectomy, many women report impaired sexual functioning despite estrogen replacement. We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced menopause.Seventy-five women, 31 to 56 years old, who had undergone oophorectomy (...) and hysterectomy received conjugated equine estrogens (at least 0.625 mg per day orally) and, in random order, placebo, 150 microg of testosterone, and 300 microg of testosterone per day transdermally for 12 weeks each. Outcome measures included scores on the Brief Index of Sexual Functioning for Women, the Psychological General Well-Being Index, and a sexual-function diary completed over the telephone.The mean (+/-SD) serum free testosterone concentration increased from 1.2+/-0.8 pg per milliliter (4.2+/-2.8

2000 NEJM

106. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. (PubMed)

Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. Androstenedione, a precursor to testosterone, is marketed to increase blood testosterone concentrations as a natural alternative to anabolic steroid use. However, whether androstenedione actually increases blood testosterone levels or produces anabolic androgenic effects is not known.To determine if short- and long-term oral androstenedione supplementation (...) in men increases serum testosterone levels and skeletal muscle fiber size and strength and to examine its effect on blood lipids and markers of liver function.Eight-week randomized controlled trial conducted between February and June 1998.Thirty healthy, normotestosterogenic men (aged 19-29 years) not taking any nutritional supplements or androgenic-anabolic steroids or engaged in resistance training.Twenty subjects performed 8 weeks of whole-body resistance training. During weeks 1, 2, 4, 5, 7

1999 JAMA

107. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. (PubMed)

The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. Athletes often take androgenic steroids in an attempt to increase their strength. The efficacy of these substances for this purpose is unsubstantiated, however.We randomly assigned 43 normal men to one of four groups: placebo with no exercise; testosterone with no exercise; placebo plus exercise; and testosterone plus exercise. The men received injections of 600 mg of testosterone enanthate (...) or placebo weekly for 10 weeks. The men in the exercise groups performed standardized weight-lifting exercises three times weekly. Before and after the treatment period, fat-free mass was determined by underwater weighing, muscle size was measured by magnetic resonance imaging, and the strength of the arms and legs was assessed by bench-press and squatting exercises, respectively.Among the men in the no-exercise groups, those given testosterone had greater increases than those given placebo in muscle

1996 NEJM

108. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. (PubMed)

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. Insulin resistance and increased ovarian cytochrome P450c17 alpha activity are both features of the polycystic ovary syndrome. P450c17 alpha, which is involved in androgen biosynthesis, has both 17 alpha-hydroxylase and 17,20-lyase activities. Increased activity of this enzyme results in exaggerated conversion of progesterone to 17 alpha (...) in the leuprolide-stimulated peak serum 17 alpha-hydroxyprogesterone concentration from 455 +/- 54 to 281 +/- 52 ng per deciliter (13.7 +/- 1.6 to 8.5 +/- 1.6 nmol per liter) (P = 0.01). The serum 17 alpha-hydroxyprogesterone values increased slightly in the placebo group. In the metformin group, the basal serum luteinizing hormone concentration decreased from 8.5 +/- 2.2 to 2.8 +/- 0.5 mlU per milliliter (P = 0.01), the serum free testosterone concentration decreased from 0.34 +/- 0.07 to 0.19 +/- 0.05 ng per

1996 NEJM

109. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. (PubMed)

Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. In a double-blind trial oestradiol, oestradiol/testosterone, or placebo implants were assessed for their effects on psychological symptoms in women attending a menopause clinic. After two months, women receiving active treatment scored better than the placebo group on a self-rating scale of distress, on anxiety, and on depression (p less than 0.05). Postmenopausal but not perimenopausal women improved

1987 Lancet